Klotho to acquire Turn Biotechnologies' assets [Yahoo! Finance]
Klotho Neurosciences, Inc. (KLTO)
Company Research
Source: Yahoo! Finance
Turn Biotechnologies is focused on induced pluripotent stem cells (iPSCs) and cellular reprogramming. Klotho has signed a letter of intent (LOI) in this regard. The cash and stock deal is contingent upon the completion of due diligence, the execution of a definitive agreement and fulfilment of typical closing conditions. Under the LOI's terms, Klotho would gain control of Turn's Epigenetic Reprogramming of Age (ERA) platform and the eTurna RNA delivery system. Developed at Stanford University in the US, and exclusively licensed by the institution, the ERA platform leverages the eTurna system. These technologies are intended for restoring the function of tissues and rejuvenating somatic cells, potentially leading to a variety of regenerative therapies in ophthalmology, dermatology, osteoarthritis, muscle health, immunology and amyotrophic lateral sclerosis (ALS). A key aspect of the transaction is Klotho's acquisition of an out-licensing and joint development partnership w
Show less
Read more
Impact Snapshot
Event Time:
KLTO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KLTO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KLTO alerts
High impacting Klotho Neurosciences, Inc. news events
Weekly update
A roundup of the hottest topics
KLTO
News
- Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' AwardPR Newswire
- Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in BostonPR Newswire
- Klotho Neurosciences Announces Expiration of Letter of Intent [Yahoo! Finance]Yahoo! Finance
- Klotho Neurosciences Announces Expiration of Letter of IntentPR Newswire
- Klotho Neurosciences to acquire select assets from Turn Biotechnologies [Seeking Alpha]Seeking Alpha
KLTO
Sec Filings
- 12/5/25 - Form S-1
- 11/13/25 - Form 10-Q
- 11/6/25 - Form S-8
- KLTO's page on the SEC website